Furthermore the results from the WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, meta-analysis on only RCTs, confirmed our conclusion that IL-6 (receptor) antagonists are associated with lower mortality for patients with COVID-1922. The gene discussed is IL6; the disease is COVID-19.